|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
The Week in Review: Company Profiles and Drug Advancement
8/4/2008 3:37:37 PM
August 2, 2008 -- In ChinaBio® Today, we profiled two China biotechs last week. One, Shenogen Pharma Group, won one of the two “Most Promising Company” awards at the recent ChinaBio® Investor Forum, The other profiled company, Beike Biotechnology, provides stem cell treatments for a variety of difficult-to-treat maladies. Bridge Labs announced plans to build a second preclinical facility in China; Lotus Pharma (OTCBB: LTUS) will construct a manufacturing plant in Inner Mongolia; Zhejiang Huahai Pharma (SHSE: 600521) will provide finished product, not just APIs, to Merck (NYSE: MRK); Tianyin Pharma (OTCBB: TYNP) was given SFDA approval for a generic version of the statin simvastatin; CompuMed (OTCBB: CMPD) received approval from the SFDA to market its osteoporosis diagnostic software in China; Bayer and Onyx Pharmas (NYSE: ONYX) were awarded SFDA approval for their cancer drug, Nexavar®; Huifeng Bio-Pharmaceutical (OTCBB: HFGB) remains on track to gain approval to provide Diosmin to Safic-Alcan; NovaMed Pharma added a sixth drug to the list of pharmaceutical products it distributes in China for Sanofi-Aventis (NYSE: SNY); and Sinobiomed (OTCBB: SOBM) received part of a new $500,000 funding. More details...
|
|
|
|
|
|
|
|
|
|
|